The successful treatment of HIV through combinations of antiretroviral drugs significantly improved patient outcomes but earlier therapies had the unintended side effect of causing lipodystrophy. In recent years, the development of less toxic drugs has reduced the incidence of lipodystrophy, but growing evidence suggests that newer treatments may promote obesogenesis in people living with HIV. Marta Giralt addressed this topic as a speaker at the seminar “Metabolic Disorders in People with HIV: From Basic to Clinical,” organized by GeSIDA, the study group of SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiology), focused specifically on HIV infection and related conditions. In her presentation, Dr. Giralt shared our team’s long- standing research on adipose tissue alterations in people living with HIV.
